Keyword: Abbott Laboratories
Abbott CEO White set to step down after 21 years; Lonza head Funk out after just a year; Progenics' Baker could be out after board shuffle.
The FDA recently labeled two device recalls as Class I, the most serious, after they were launched by Philips and Abbott earlier this year.
Abbott teamed up with Omada Health to offer its FreeStyle Libre CGM system through the latter’s digital care program for type 2 diabetes.
After ponying up more than $800 million on its deal with Reata Pharmaceuticals, AbbVie is calling it quits.
Just after starting a large trial of its TriClip, Abbott presented new data from a smaller, single-arm analysis showing improvements after 6 months.
The FDA approved a “low-dose” version of Abbott’s neurostimulation system, designed to treat chronic pain for up to 10 years without recharging.
Abbott has secured FDA clearance for its highly sensitive troponin blood test, which aims to identify heart attacks hours earlier than other methods.
Abbott has received European approvals for two devices designed for children and infants with life-threatening heart defects.
Abbott and Sanofi are partnering up to develop tools that connect their respective blood sugar tracking and insulin delivery technologies.
Ayala Pharmaceuticals has hired AbbVie’s former vice president of oncology, Gary Gordon, M.D., Ph.D., as its new chief medical officer.